Last reviewed: May 14, 2026 Last updated: May 14, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The study, published Wednesday in The BMJ , a globally respected peer-reviewed British medical journal, followed patients for an average of 2.7 years and found that the increased risk was concentrated in non-scarring alopeciaa type of hair loss that does not permanently destroy the follicles
[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Bigal M.E., Lipton R.B., Holland P.R., Goadsby P.J
doi: 10.1210/jc.2018-00528 18 McIntyreHDMaABirdDMPatersonCARavenscroftPJCameronDP
Semaglutide and tirzepatide are GLP-1 (glucagon-like peptide-1) receptor antagonists